Advisory Services Network’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $807K | Buy |
16,965
+2,121
| +14% | +$112K | 0.01% | 1034 |
|
|
2025
Q4 | $778K | Buy |
14,844
+1,024
| +7% | +$61.3K | 0.01% | 996 |
|
|
2025
Q3 | $896K | Buy |
13,820
+350
| +3% | +$20.1K | 0.01% | 918 |
|
|
2025
Q2 | $758K | Buy |
13,470
+3,509
| +35% | +$136K | 0.01% | 952 |
|
|
2025
Q1 | $339K | Sell |
9,961
-96
| -1% | -$4.07K | 0.01% | 1228 |
|
|
2024
Q4 | $396K | Sell |
10,057
-7,629
| -43% | -$360K | 0.01% | 1150 |
|
|
2024
Q3 | $955K | Hold |
17,686
| – | – | 0.02% | 731 |
|
|
2024
Q2 | $955K | Buy |
17,686
+112
| +0.6% | +$6.48K | 0.02% | 731 |
|
|
2024
Q1 | $1.2M | Sell |
17,574
-100
| -0.6% | -$7.16K | 0.03% | 622 |
|
|
2023
Q4 | $1.11M | Buy |
17,674
+3,854
| +28% | +$213K | 0.03% | 595 |
|
|
2023
Q3 | $627K | Sell |
13,820
-706
| -5% | -$36.5K | 0.02% | 815 |
|
|
2023
Q2 | $815K | Buy |
14,526
+170
| +1% | +$9.65K | 0.02% | 698 |
|
|
2023
Q1 | $649K | Buy |
14,356
+11,907
| +486% | +$578K | 0.02% | 792 |
|
|
2022
Q4 | $99.6K | Sell |
2,449
-635
| -21% | -$33.7K | ﹤0.01% | 1622 |
|
|
2022
Q3 | $202K | Sell |
3,084
-3,203
| -51% | -$232K | 0.01% | 1202 |
|
|
2022
Q2 | $382K | Sell |
6,287
-7,133
| -53% | -$419K | 0.01% | 950 |
|
|
2022
Q1 | $842K | Buy |
13,420
+1,069
| +9% | +$67.1K | 0.02% | 680 |
|
|
2021
Q4 | $936K | Sell |
12,351
-435
| -3% | -$38K | 0.03% | 645 |
|
|
2021
Q3 | $1.43M | Buy |
12,786
+337
| +3% | +$42.3K | 0.05% | 478 |
|
|
2021
Q2 | $2.02M | Buy |
12,449
+2,291
| +23% | +$279K | 0.06% | 391 |
|
|
2021
Q1 | $1.24M | Buy |
10,158
+1,848
| +22% | +$279K | 0.05% | 477 |
|
|
2020
Q4 | $1.27M | Buy |
8,310
+7,169
| +628% | +$847K | 0.05% | 422 |
|
|
2020
Q3 | $95K | Buy |
+1,141
| New | +$101K | ﹤0.01% | 1277 |
|
|
2020
Q2 | – | Sell |
-674
| Closed | -$29K | – | 1360 |
|
|
2020
Q1 | $29K | Hold |
674
| – | – | ﹤0.01% | 1645 |
|
|
2019
Q4 | $41K | Buy |
674
+400
| +146% | +$21.8K | ﹤0.01% | 1597 |
|
|
2019
Q3 | $13K | Hold |
274
| – | – | ﹤0.01% | 2039 |
|
|
2019
Q2 | $13K | Buy |
274
+200
| +270% | +$7.99K | ﹤0.01% | 2037 |
|
|
2019
Q1 | $3K | Hold |
74
| – | – | ﹤0.01% | 2226 |
|
|
2018
Q4 | $2K | Hold |
74
| – | – | ﹤0.01% | 2289 |
|
|
2018
Q3 | $3K | Hold |
74
| – | – | ﹤0.01% | 2207 |
|
|
2018
Q2 | $4K | Sell |
74
-921
| -93% | -$52.5K | ﹤0.01% | 2089 |
|
|
2018
Q1 | $45K | Buy |
+995
| New | +$41.1K | ﹤0.01% | 1360 |
|
|
2017
Q4 | – | Sell |
-100
| Closed | -$2K | – | 2542 |
|
|
2017
Q3 | $2K | Hold |
100
| – | – | ﹤0.01% | 2132 |
|
|
2017
Q2 | $2K | Hold |
100
| – | – | ﹤0.01% | 2089 |
|
|
2017
Q1 | $2K | Buy |
+100
| New | +$1.96K | ﹤0.01% | 1951 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Advisory Services Network's CRSP Position: Q1 2026 in Review
Advisory Services Network increased its CRISPR Therapeutics (CRSP) stake by 14% in Q1 2026, buying an estimated $112K and bringing the position to 16,965 shares worth $807K. The position accounts for 0.01% of the portfolio, ranked #1034.
Advisory Services Network first reported a position in CRSP in Q1 2017 and has held it in 35 quarters since. The position peaked at $2.02M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- Advisory Services Network held 16,965 shares of CRISPR Therapeutics worth $807K as of Q1 2026.
- Advisory Services Network bought 2,121 CRISPR Therapeutics shares in Q1 2026, an estimated $112K.
- CRISPR Therapeutics made up 0.01% of Advisory Services Network's portfolio in Q1 2026, its #1034 holding.
- Advisory Services Network first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 35 quarters since.
- Advisory Services Network's CRISPR Therapeutics position peaked at $2.02M in Q2 2021.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on Advisory Services Network's 13F filing for Q1 2026, filed 15 May 2026.